Clinical Trials in Maroochydore, Australia
6 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011
Recruiting
Phase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Janssen Research & Development, LLC750 enrolled214 locationsNCT06807424
Recruiting
The Australian HCV Point-of-Care Testing Program
Hepatitis C
Kirby Institute60,000 enrolled69 locationsNCT05042544
Recruiting
Phase 1Phase 2
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
Eupraxia Pharmaceuticals Inc.117 enrolled23 locationsNCT05608681
Recruiting
Phase 3
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
Systemic Lupus Erythematosus
Novartis Pharmaceuticals550 enrolled127 locationsNCT06133972
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 2
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
Celiac Disease
Teva Branded Pharmaceutical Products R&D LLC48 enrolled21 locationsNCT06807463
Recruiting
Phase 2
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC)UC - Ulcerative Colitis
Odyssey Therapeutics57 enrolled32 locationsNCT06850727
Recruiting
Phase 2
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Sjögren's Syndrome
Lubris Bio Pty Ltd80 enrolled6 locationsNCT07118241
Recruiting
Early Phase 1
G.I. Pharmacokinetics of LMN-401 in Individuals With Ileostomies
Travelers Diarrhea
Lumen Bioscience, Inc.12 enrolled1 locationNCT06556940